Pseudolymphoma associated with calcium channel blockers: a FAERS disproportionality analysis comparing dihydropyridines and non-dihydropyridines
Canadian Journal of Physiology and Pharmacology · 01.01.2026 · 104 · 1-5
DOI: 10.1139/cjpp-2025-0406 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.01.2026. Verfasst von Connor Frey. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Dihydropyridines, Pseudolymphoma, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Calcium channel blockers (CCBs), particularly amlodipine, are among the most widely prescribed antihypertensive agents globally. However, no comprehensive disproportionality analysis has quantified this association. This pharmacovigilance study utilized the FDA Adverse Event Reporting System (FAERS) to evaluate the reporting association between CCBs and pseudolymphoma. The FAERS database was parsed through its 14 104 743 adverse event reports. Five CCBs were evaluated: three dihydropyridines (amlodipine, nifedipine, and felodipine) and two non-dihydropyridines (diltiazem, verapamil). Disproportionality was quantified using reporting odds ratios (RORs). The MedDRA preferred term “pseudolymphoma” was employed for case identification. Among 319 pseudolymphoma reports, 44 were associated with dihydropyridines and 1 with non-dihydropyridines. Amlodipine demonstrated the strongest signal (ROR 38.08, 95% CI 27.60–52.54; n = 42), followed by nifedipine (ROR 18.61, 95% CI 4.64–74.74; n = 2). Diltiazem showed a non-significant signal (ROR 5.47, 95% CI 0.77–38.93; n = 1). Felodipine and verapamil yielded no reports. Dihydropyridines exhibited 7- to 70-fold greater RORs compared with non-dihydropyridines. This analysis establishes a robust, though not causal, class-specific safety signal linking dihydropyridine CCBs, particularly amlodipine, to pseudolymphoma risk. The substantial disproportionality suggests a pharmacologically mediated mechanism requiring heightened clinical surveillance, prompt recognition, and timely drug discontinuation to prevent potential malignant transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Connor Frey
Zitieren
APA
Frey, C. (2026). Pseudolymphoma associated with calcium channel blockers: a FAERS disproportionality analysis comparing dihydropyridines and non-dihydropyridines. Canadian Journal of Physiology and Pharmacology, 104, 1-5. https://doi.org/10.1139/cjpp-2025-0406
Vancouver
Frey C. Pseudolymphoma associated with calcium channel blockers: a FAERS disproportionality analysis comparing dihydropyridines and non-dihydropyridines. Canadian Journal of Physiology and Pharmacology. 2026;104:1-5. doi:10.1139/cjpp-2025-0406
BibTeX
@article{Frey2026,
author = {Frey, Connor},
title = {Pseudolymphoma associated with calcium channel blockers: a FAERS disproportionality analysis comparing dihydropyridines and non-dihydropyridines},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
volume = {104},
pages = {1--5},
doi = {10.1139/cjpp-2025-0406}
}
EUVIMED